KPTI Stock Analysis: Karyopharm Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 216m USD | 12M Return: 137.6% | Charts, Fundamentals & Technical Analysis

Oncology Drugs, Nuclear Export Inhibitors, SINE Compounds, Cancer Therapeutics
Total Rating 47
Safety 43
Buy Signal 0.59
Biotechnology
Industry Rotation: +30.9
Market Cap: 216M
Avg Turnover: 3.62M
Risk 3d forecast
Volatility83.4%
VaR 5th Pctl13.2%
VaR vs Median-3.89%
Reward TTM
Sharpe Ratio1.33
Rel. Str. IBD92.9
Rel. Str. Peer Group63
Character TTM
Beta0.960
Beta Downside0.367
Hurst Exponent0.596
Drawdowns 3y
Max DD86.96%
CAGR/Max DD-0.30
CAGR/Mean DD-0.45
EPS (Earnings per Share) EPS (Earnings per Share) of KPTI over the last years for every Quarter: "2021-06": -10.65, "2021-09": -10.35, "2021-12": 6.9, "2022-03": -7.95, "2022-06": -9.3, "2022-09": -6.75, "2022-12": -6.45, "2023-03": -4.5, "2023-06": -4.35, "2023-09": -4.5, "2023-12": -0.36, "2024-03": -4.8, "2024-06": -4.34, "2024-09": -3.9, "2024-12": -3.6, "2025-03": -2.77, "2025-06": -4.07, "2025-09": -3.82, "2025-12": -2.23, "2026-03": -1.24,
Last SUE: 0.62
Qual. Beats: 0
Revenue Revenue of KPTI over the last years for every Quarter: 2021-06: 22.601, 2021-09: 37.689, 2021-12: 126.269, 2022-03: 47.67, 2022-06: 39.679, 2022-09: 36.145, 2022-12: 33.58, 2023-03: 38.698, 2023-06: 37.579, 2023-09: 36.009, 2023-12: 33.747, 2024-03: 33.126, 2024-06: 42.786, 2024-09: 38.783, 2024-12: 30.542, 2025-03: 30.015, 2025-06: 37.929, 2025-09: 44.044, 2025-12: 34.079, 2026-03: 35.066,
Rev. CAGR: 0.01%
Rev. Trend: 0.5%
Last SUE: 0.96
Qual. Beats: 1

Warnings

Negative Equity With Losses: Insolvent Profile
Strong Share Dilution
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Seasonality 10.5 years of data

Jan -1.3% 14
Feb -2.4% 11
Mar -1.7% 2
Apr -4.6% 25
May +3.6% 13
Jun +0.5% 0
Jul +0.2% 11
Aug +4.2% 6
Sep +6.0% 39
Oct +0.2% 8
Nov +7.3% 35
Dec -7.5% 35

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: KPTI Karyopharm Therapeutics

Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company founded in 2008 that discovers, develops, and markets small molecule drugs targeting nuclear export - specifically the protein XPO1 - to treat cancer and other diseases. Its lead product, XPOVIO (selinexor), is approved for adult patients with multiple myeloma (in combination with bortezomib and dexamethasone, and with dexamethasone for relapsed/refractory cases) and for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company is also advancing selinexor for additional hematological and solid tumor indications and developing a second SINE compound, eltanexor, for myeloproliferative neoplasms and TP53 wild-type solid tumors.

As a micro-cap biotechnology company (GICS sub-industry: Biotechnology), Karyopharm supplements its direct commercialization of XPOVIO in the U.S. with an out-licensing model, holding development and commercialization agreements with Menarini Group and Antengene Therapeutics for selinexor and related compounds, and a distribution agreement with FORUS Therapeutics for XPOVIO in Canada. The company also has a clinical collaboration with Bristol Myers Squibb to evaluate BMSs mezigdomide in combination with selinexor for relapsed or refractory multiple myeloma.

Headlines to Watch Out For
  • XPOVIO sales growth drives revenue in multiple myeloma and DLBCL
  • BMS mezigdomide combination trial readouts catalyst for selinexor pipeline
  • Cash runway concerns as micro cap biotech funds ongoing operating losses
Piotroski VR-10 (Strict) 2.0
Net Income: -195.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.45 > 0.02 and ΔFCF/TA 51.09 > 1.0
NWC/Revenue: 5.98% < 20% (prev 21.02%; Δ -15.04% < -1%)
CFO/TA -0.45 > 3% & CFO -59.1m > Net Income -195.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.08 > 1.5 & < 3
Outstanding Shares: last quarter (24.7m) vs 12m ago 191.8% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 116.6% > 50% (prev 111.3%; Δ 5.35% > 0%)
Interest Coverage Ratio: -3.12 > 6 (EBIT TTM -148.1m / Interest Expense TTM 47.4m)
Altman Z'' -15.00
A: 0.07 (Total Current Assets 126.3m - Total Current Liabilities 117.3m) / Total Assets 131.4m
B: -13.56 (Retained Earnings -1.78b / Total Assets 131.4m)
C: -1.14 (EBIT TTM -148.1m / Avg Total Assets 129.6m)
D: -0.67 (Book Value of Equity -265.6m / Total Liabilities 397.1m)
Altman-Z'' = -52.14 = D
Beneish M -3.79
DSRI: 0.62 (Receivables 23.4m/35.2m, Revenue 151.1m/142.1m)
GMI: 1.00 (GM 96.14% / 96.03%)
AQI: 0.34 (AQ_t 0.00 / AQ_t-1 0.01)
SGI: 1.06 (Revenue 151.1m / 142.1m)
TATA: -1.03 (NI -195.0m - CFO -59.1m) / TA 131.4m)
Beneish M = -3.79 (Cap -4..+1) = AAA
What is the price of KPTI shares?

As of July 08, 2026, the stock is trading at USD 10.05 with a total of 249,504 shares traded. Over the past week, the price has changed by -0.35%, over one month by +18.24%, over three months by +39.39% and over the past year by +137.59%.

Current recommended Stop Loss: 9.20 (which is 8.5% or 1.2 ATR below the current price).

Is KPTI a buy, sell or hold?

Karyopharm Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy KPTI.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KPTI price?
Analysts Target Price 13.5 34.3%
Karyopharm Therapeutics (KPTI) - Fundamental Data Overview as of 03 July 2026
Market Cap USD = 216.4m (216.4m USD * 1.0 USD.USD)
P/S = 1.4322
P/B = 12.0484
P/EG = -0.15
Revenue TTM = 151.1m USD
EBIT TTM = -148.1m USD
EBITDA TTM = -147.9m USD
Long Term Debt = 192.2m USD (from longTermDebt, last quarter)
Short Term Debt = 33.2m USD (from shortTermDebt, last quarter)
Debt = 237.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.49m
Net Debt = 146.5m USD (calculated: Debt 237.4m - CCE 90.8m)
Enterprise Value = 362.9m USD (216.4m + Debt 237.4m - CCE 90.8m)
Interest Coverage Ratio = -3.12 (Ebit TTM -148.1m / Interest Expense TTM 47.4m)
EV/FCF = -6.14x (Enterprise Value 362.9m / FCF TTM -59.1m)
FCF Yield = -16.29% (FCF TTM -59.1m / Enterprise Value 362.9m)
FCF Margin = -39.12% (FCF TTM -59.1m / Revenue TTM 151.1m)
Net Margin = -129.0% (Net Income TTM -195.0m / Revenue TTM 151.1m)
 Gross Margin = unknown ((Revenue TTM 151.1m - Cost of Revenue TTM 6.00m) / Revenue TTM)
 Tobins Q-Ratio = 2.76 (Enterprise Value 362.9m / Total Assets 131.4m)
Interest Expense / Debt = 19.97% (Interest Expense 47.4m / Debt 237.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -117.0m (EBIT -148.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.08 (Total Current Assets 126.3m / Total Current Liabilities 117.3m)
 Debt / Equity = -0.89 (negative equity) (Debt 237.4m / totalStockholderEquity, last quarter -265.6m)
 Debt / EBITDA = -0.99 (negative EBITDA) (Net Debt 146.5m / EBITDA -147.9m)
 Debt / FCF = -2.48 (negative FCF - burning cash) (Net Debt 146.5m / FCF TTM -59.1m)
 Total Stockholder Equity = -266.7m (last 4 quarters mean from totalStockholderEquity)
 RoA = -150.5% (out of range, set to none)
 RoE = 73.11% (negative equity) (Net Income TTM -195.0m / Total Stockholder Equity -266.7m)
 RoCE = 198.7% (negative capital employed) (EBIT -148.1m / Capital Employed (Equity -266.7m + L.T.Debt 192.2m))
 RoIC = -293.9% (out of range, set to none) (NOPAT -117.0m / Invested Capital 39.8m)
 WACC = 12.72% (E(216.4m)/V(453.8m) * Re(9.36%) + D(237.4m)/V(453.8m) * Rd(19.97%) * (1-Tc(0.21)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 68.39%
 [DCF] Fair Price = unknown (Cash Flow -59.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.62 | # QB: 0
Revenue Correlation: 0.53 | Revenue CAGR: 0.01% | SUE: 0.96 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-1.39 | Chg30d=+0.00% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-1.21 | Chg30d=+0.00% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-4.95 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+59.5% | GrowthRev=-6.1%
EPS next Year (2027-12-31): EPS=-4.89 | Chg30d=-12.03% | Revisions=-25% | GrowthEPS=+1.3% | GrowthRev=+13.2%
[Analyst] Revisions Ratio: -29% (up=1, down=3)